Gubra – Presentation of Q2 report 2023

Meet and ask questions to Gubra’s CEO Henrik Blou and CFO Kristian Borbos on 28 August at 10.00 am CEST when they present the Q2 report 2023 and the latest development.

Gubra has two divisions CRO and D&P, and late in the quarter the company acquired a research service provider MiniGut ApS to the CRO division.

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information. Gubra is listed on Nasdaq Copenhagen mid Cap, with ticker code GUBRA.

Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 14:30, 05-07-2023.